Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Biemar F, Foti M. Global progress against cancer—challenges and opportunities. Cancer Biol Med. 2013;10(4):183.

PubMed  PubMed Central  Google Scholar 

Chakraborty S, Rahman T. The difficulties in cancer treatment. Ecancermedicalscience. 2012;6:ed16.

PubMed  PubMed Central  Google Scholar 

El-Sayes N, Vito A, Mossman K. Tumor heterogeneity: a great barrier in the age of cancer immunotherapy. Cancers. 2021;13(4):806.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun X-X, Yu Q. Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacologica Sinica. 2015;36(10):1219–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lei ZN, Tian Q, Teng QX, Wurpel JN, Zeng L, Pan Y, et al. Understanding and targeting resistance mechanisms in cancer. MedComm. 2023;4(3):e265.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salemme V, Centonze G, Avalle L, Natalini D, Piccolantonio A, Arina P, et al. The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity. Front Oncol. 2023;13:1170264.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hummelgaard S, Vilstrup JP, Gustafsen C, Glerup S, Weyer K. Targeting PCSK9 to tackle cardiovascular disease. Pharmacol Ther. 2023;249:108480.

Article  CAS  PubMed  Google Scholar 

Nicholls SJ. PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives. Kardiologia Polska (Pol Heart J). 2023. https://doi.org/10.33963/KP.a2023.0030.

Article  Google Scholar 

Wang R, Liu H, He P, An D, Guo X, Zhang X, et al. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8+T cells and the exclusion of Treg cells. Front Immunol. 2022;13:947756.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu Y, Lin X, Dong Y, Wood G, Seidah NG, Werstuck G, et al. PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. J Exp Clin Cancer Res. 2023;42(1):1–27.

Article  Google Scholar 

Quagliariello V, Bisceglia I, Berretta M, Iovine M, Canale ML, Maurea C, et al. PCSK9 inhibitors in cancer patients treated with immune-checkpoint inhibitors to reduce cardiovascular events: new frontiers in cardioncology. Cancers. 2023;15(5):1397.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rada M, Krzywon L, Kapelanski-Lamoureux A, Petrillo S, Reynolds A, Lazaris A, et al. Inhibition of pcsk9 impairs the development of vessel co-option and potentiates anti-angiogenic therapy in colorectal cancer liver metastases. Cancer Res. 2023;83(7_Supplement):1741.

Article  Google Scholar 

Seidah NG, Prat A. The multifaceted biology of PCSK9. Endocr Rev. 2022;43(3):558–82.

Article  PubMed  Google Scholar 

Wong CC, Wu J-L, Ji F, Kang W, Bian X, Chen H, et al. The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC/KRAS-mutant colorectal cancer. Nat Commun. 2022;13(1):3971.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu B, Li S, Fang Y, Zou Y, Song D, Zhang S, et al. Proprotein convertase subtilisin/kexin type 9 promotes gastric cancer metastasis and suppresses apoptosis by facilitating MAPK signaling pathway through HSP70 up-regulation. Front Oncol. 2021;10:609663.

Article  PubMed  PubMed Central  Google Scholar 

Fang S, Yarmolinsky J, Gill D, Bull CJ, Perks CM, Consortium P, et al. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study. PLoS Med. 2023;20(1):e1003988.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun Y, Zhang H, Meng J, Guo F, Ren D, Wu H, et al. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway. Cell Rep. 2022;40(7):111194.

Article  CAS  PubMed  Google Scholar 

Wong Chong E, Joncas F-H, Seidah NG, Calon F, Diorio C, Gangloff A. Circulating levels of PCSK9, ANGPTL3 and Lp (a) in stage III breast cancers. BMC Cancer. 2022;22(1):1–12.

Article  Google Scholar 

Gao X, Yi L, Jiang C, Li S, Wang X, Yang B, et al. PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer. Front Immunol. 2023;14:1142428.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oza PP, Kashfi K. The evolving landscape of PCSK9 inhibition in cancer. Eur J Pharmacol. 2023;949:175721.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seidah NG, Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med. 2007;85:685–96.

Article  CAS  PubMed  Google Scholar 

Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA, Spraggon G. The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain. Proceed Natl Acad Sci. 2007;104(37):14604–96.

Article  CAS  Google Scholar 

Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure. 2007;15(5):545–52.

Article  CAS  PubMed  Google Scholar 

Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004;279(47):48865–75.

Article  CAS  PubMed  Google Scholar 

Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci. 2003;100(3):928–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferri N, Tibolla G, Pirillo A, Cipollone F, Mezzetti A, Pacia S, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220(2):381–6.

Article  CAS  PubMed  Google Scholar 

Ding Z, Liu S, Wang X, Deng X, Fan Y, Shahanawaz J, et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res. 2015;107(4):556–67.

Article  PubMed  Google Scholar 

Ma M, Hou C, Liu J. Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: focus on immune regulation. Front Cardiovasc Med. 2023;10:1148486.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen H, Chen X. PCSK9 inhibitors for acute coronary syndrome: the era of early implementation. Front Cardiovasc Med. 2023;10:1138787.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turner TA, Stein EA. Targeting PCSK9 inhibitors to those who will benefit most. Lancet Diabetes Endocrinol. 2022;10(5):301–3.

Article  CAS